Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Phase 1/2 Unknown 15 enrolled Senesco Technologies, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia patients when given by intravenous infusion at various doses.

Timeline

Start: 2011-09
Primary completion: 2014-10
Completion: 2014-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SNS01-T	Unknown	0.0125 mg/kg	Intravenous
Subject	SNS01-T	Unknown	0.05 mg/kg	Intravenous
Subject	SNS01-T	Unknown	0.2 mg/kg	Intravenous
Subject	SNS01-T	Unknown	0.375 mg/kg	Intravenous

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Summary

Timeline

Drugs

Indications